BlockBeats News, January 20th, AI-driven derivative trading platform Perpetuals com (PDC), founded by former FTX Europe (FTX EU) core members, officially debuted on Tuesday with its stock trading on Nasdaq. The platform was co-founded by Patrick Gruhn and Robin Matzke, who were former co-founders of Swiss digital asset company Digital Assets, which was acquired by Sam Bankman-Fried in 2021 and rebranded as FTX EU.
The launch of Perpetuals com followed the business integration of Perpetual Markets Ltd. after its acquisition by Earlyworks Co. The company stated that its platform offers regulated 7x24-hour self-clearing trading and blockchain-based settlement technology.
Following the bankruptcy of FTX's parent company, Gruhn and Matzke successfully repurchased the remaining assets of FTX EU after a long legal process and quietly developed the Perpetuals platform. Gruhn mentioned that this process provided the company with a vast amount of retail trading data used to train its AI and machine learning systems.
Perpetuals' AI system is reportedly trained on over 10 million trade histories from multiple mainstream crypto exchanges, allowing it to analyze market sentiment and calculate individual traders' probability of profit and loss to help options issuers, market makers, and others optimize hedging strategies. The company aims to provide innovative products to the market as an alternative to traditional CFDs (Contract for Difference) and perpetual contracts, using AI-enhanced derivatives to reduce retail investors' potential losses in a long-standing environment seen as unfair or even predatory through AI-enhanced derivatives.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.






Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.















Long-end U.S. Treasury yields surged to multi-year highs, pressuring technology, semiconductor, storage, and optical communication stocks and driving a clear cooling in market risk appetite. At the same time, Anthropic’s revenue came in below some bullish expectations, prompting investors to reassess the AI growth narrative; Unitree Robotics officially listed on the STAR Market, extending momentum in robotics and embodied AI; while SpaceX and other commercial space names showed relative resilience. Investors are now focused on tonight’s Federal Reserve minutes for clearer signals on the policy path and broader market sentiment.









Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.